Gerardus Bos (G.M.J.)

Ehlers, F. A. I., Blise, K. E., Betts, C. B., Sivagnanam, S., Kooreman, L. F. S., Hwang, E. S., Bos, G. M. J., Wieten, L., & Coussens, L. M. (2025). Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers. Breast Cancer Research, 27(1), Article 14. https://doi.org/10.1186/s13058-025-01964-4

Mai, E. K., Nogai, A., Lokhorst, H. M., van der Holt, B., Zweegman, S., Weisel, K. C., Croockewit, S., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Bos, G. M. J., Brossart, P., Ypma, P., Hanoun, C., Bertsch, U., Hielscher, T., Salwender, H. J., ... Sonneveld, P. (2024). Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial. HemaSphere, 8(11), Article e70052. https://doi.org/10.1002/hem3.70052

Beelen, N. A., Valckx, V. T. C., Bos, G. M. J., & Wieten, L. (2024). Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy. Best Practice & Research Clinical Haematology, 37(3), Article 101568. https://doi.org/10.1016/j.beha.2024.101568

Gong, Y., Germeraad, W. T. V., Zhang, X., Wu, N., Li, B., Janssen, L., He, Z., Gijbels, M. J. J., Wu, B., Gijsbers, B. L. M. G., Olieslagers, T. I., Bos, G. M. J., Zheng, L., & Klein Wolterink, R. G. J. (2024). NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody. Molecular Therapy, 32(8), 2711-2727. https://doi.org/10.1016/j.ymthe.2024.06.034

Minnema, M. C., Nasserinejad, K., Hegenbart, U., Ypma, P. F., Wu, K. L., Kersten, M. J., Croockewit, S., Zweegman, S., Tick, L., Broijl, A., Koene, H., Bos, G. M. J., Sonneveld, P., & Schonland, S. O. (2024). HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients. eJHaem, 5(4), 815-819. https://doi.org/10.1002/jha2.918

Beelen, N. A., Molenbroeck, S. J. J., Groeneveld, L., Voorter, C. E., Bos, G. M. J., & Wieten, L. (2024). HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma. Immunogenetics, 76(3), 155-164. https://doi.org/10.1007/s00251-024-01336-w

Beelen, N. A., Aberle, M. R., Bruno, V., Olde Damink, S. W. M., Bos, G. M. J., Rensen, S. S., & Wieten, L. (2023). Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Frontiers in Immunology, 14(1), Article 1133796. https://doi.org/10.3389/fimmu.2023.1133796

Ehlers, F. A. I., Mahaweni, N. M., van de Waterweg Berends, A., Saya, T., Bos, G. M. J., & Wieten, L. (2023). Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages. Cancer Immunology Immunotherapy, 72(6), 1789-1801. https://doi.org/10.1007/s00262-022-03365-4

Verkleij, C. P. M., Frerichs, K. A., Broekmans, M. E. C., Duetz, C., O'Neill, C. A., Bruins, W. S. C., Homan-Weert, P. M., Minnema, M. C., Levin, M. D., Broijl, A., Bos, G. M. J., Kersten, M. J., Klein, S. K., Shikhagaie, M. M., Casneuf, T., Abraham, Y., Smets, T., Vanhoof, G., Cortes-Selva, D., ... van de Donk, N. W. C. J. (2023). NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma. HemaSphere, 7(5), Article e881. https://doi.org/10.1097/HS9.0000000000000881

Beelen, N. A., Ehlers, F. A. I., Bos, G. M. J., & Wieten, L. (2023). Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunology Immunotherapy, 72(4), 797-804. https://doi.org/10.1007/s00262-022-03299-x